

APPENDIX 5
FORMS RELATING TO LISTING
FORM F
THE GROWTH ENTERPRISE MARKET (GEM)
COMPANY INFORMATION SHEET

Case Number: _____

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name: Baytacare Pharmaceutical Co., Ltd.

Stock code (ordinary shares): 8197

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of the Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 19 June 2017.

A. General

Place of incorporation: The People's Republic of China

Date of initial listing on GEM: 28 February 2002

Name of Sponsor(s): N/A

Names of directors: ***Executive Directors:***

(please distinguish the status of the directors Wang Shaoyan

- Executive, Non-Executive or Independent Cui Bingyan

Non-Executive) Jiang Xiaobin

Non-executive Directors:

Shi Peng

Cao Yang

Independent non-executive Directors:

Hui Lai Yam

Gao Zhikai

Yang Yulin

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Name(s) of substantial shareholder(s): (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company	Name	Number of shares	Approximate percentage of issued shares
	Beijing Baoying Chuangfu Investment Management Center (Limited Partnership)* (北京寶盈創富投資管理中心(有限合伙))	398,534,660 domestic shares	approximately 65.37% of the total issued domestic shares of the Company and approximately 46.44% of the total issued shares of the Company
	Guo Feng	137,611,830 domestic shares	approximately 22.57% of the total issued domestic shares of the Company and approximately 16.04% of the total issued shares of the Company

**for identification purpose only*

Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company:	N/A
Financial year end date:	31 December
Registered address:	No.3, No.2 Road, Jilin High-tech Development Zone, Jilin Province, The People's Republic of China
Head office and principal place of business:	No.3, No.2 Road, Jilin High-tech Development Zone, Jilin Province, The People's Republic of China
Web-site address (if applicable):	www.baytacare.com
Share registrar:	Computershare Hong Kong Investor Services Limited 17M th Floor Hopewell Centre 183 Queen's Road East Hong Kong
Auditors:	Pan-China (H.K.) CPA Limited 11/F, Hong Kong Trade Centre 161-167 Des Voeux Road Central Hong Kong

B. Business activities

Development, manufacture and sale of medicines, development of health-related big data and investment holdings in The People's Republic of China

C. Ordinary shares

Number of ordinary shares in issue:	858,054,240 (comprising 248,400,000 H shares and 609,654,240 domestic shares)
Par value of ordinary shares in issue:	H shares – RMB0.10 each Domestic shares – RMB0.10 each
Board lot size (in number of shares):	10,000

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Name of other stock exchange(s) on which ordinary shares are also listed: N/A

D. Warrants

Stock code: N/A

Board lot size: N/A

Expiry date: N/A

Exercise price: N/A

Conversion ratio: N/A
(Not applicable if the warrant is denominated in dollar value of conversion right)

No. of warrants outstanding: N/A

No. of shares falling to be issued upon the exercise of outstanding warrants: N/A

E. Other securities

Details of any other securities in issue.
(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

N/A

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Signed:

Wang Shaoyan

Cui Bingyan

Jiang Xiaobin

Shi Peng

Cao Yang

Hui Lai Yam

Gao Zhikai

Yang Yulin

NOTES

- (1) *This information sheet must be signed by or pursuant to a power of attorney for and on behalf of each of the Directors of the Company.*
- (2) *Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the GEM website a revised information sheet, together with a hard copy duly signed by or on behalf of each of the Directors, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.*
- (3) *Please send a copy of this form by facsimile transaction to Hong Kong Securities Clearing Company Limited (on 2815-9353) or such other number as may be prescribed from time to time) at the same time as the original is submitted to the Exchange.*